{"id":61275,"date":"2026-03-25T15:46:31","date_gmt":"2026-03-25T07:46:31","guid":{"rendered":"https:\/\/flcube.com\/?p=61275"},"modified":"2026-03-25T15:46:31","modified_gmt":"2026-03-25T07:46:31","slug":"zhifei-bio-initiates-phase-i-study-for-dtap-hib-quadrivalent-vaccine-component-combination-targets-pediatric-immunization-compliance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61275","title":{"rendered":"Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine \u2013 Component Combination Targets Pediatric Immunization Compliance"},"content":{"rendered":"\n

Chongqing Zhifei Biological Co., Ltd.<\/strong> (SHE: 300122<\/a>) announced the initiation of a Phase I clinical study<\/strong> for its adsorbed diphtheria-tetanus-acellular pertussis (component) and Haemophilus influenzae type b (conjugate) combination vaccine<\/strong> (DTaP-Hib). The independently developed quadrivalent vaccine<\/strong> aims to prevent four pediatric diseases<\/strong> (pertussis, diphtheria, tetanus, Hib infections) while reducing injection burden<\/strong> and improving vaccination compliance<\/strong> in China’s ~15 million annual birth cohort<\/strong>.<\/p>\n\n\n\n

Clinical Trial Overview<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
Study Phase<\/strong><\/td>Phase I (safety and immunogenicity)<\/td><\/tr>
Product<\/strong><\/td>DTaP-Hib quadrivalent combination vaccine<\/td><\/tr>
Developer<\/strong><\/td>Chongqing Zhifei Biological Co., Ltd. (SHE: 300122)<\/td><\/tr>
Vaccine Type<\/strong><\/td>Component acellular pertussis<\/strong> \u2013 DTaP + Hib conjugate<\/td><\/tr>
Target Diseases<\/strong><\/td>Pertussis, diphtheria, tetanus, Haemophilus influenzae type b (Hib) infections<\/td><\/tr>
Clinical Benefit<\/strong><\/td>Reduced injections<\/strong> vs. separate vaccinations; improved compliance<\/td><\/tr>
Announcement Date<\/strong><\/td>25\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Differentiation & Market Gap<\/h2>\n\n\n\n
Attribute<\/th>Zhifei DTaP-Hib<\/th>Current China Market<\/th><\/tr><\/thead>
Pertussis Component<\/strong><\/td>Acellular component vaccine<\/strong> \u2013 defined antigen composition, potentially improved safety profile<\/td>One licensed whole-cell DTaP-Hib<\/strong> (Sanofi) \u2013 higher reactogenicity<\/td><\/tr>
Market Position<\/strong><\/td>First component DTaP-Hib quadrivalent<\/strong> in China development<\/td>No component DTaP-Hib approved<\/strong> \u2013 unmet need for refined acellular option<\/td><\/tr>
Injection Reduction<\/strong><\/td>Single quadrivalent shot<\/strong> vs. 2\u20133 separate injections<\/td>Current schedule requires multiple visits<\/td><\/tr>
Compliance Impact<\/strong><\/td>Simplified schedule improves on-time vaccination rates<\/strong><\/td>Complex multi-dose regimens contribute to drop-out<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context & Market Opportunity<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
China Pediatric Vaccine Market<\/strong><\/td>RMB 15+ billion annually<\/strong>; combination vaccines preferred by parents and immunization programs for convenience<\/td><\/tr>
National Immunization Program (NIP)<\/strong><\/td>DTaP and Hib separately included<\/strong> in expanded NIP; combination products not yet reimbursed<\/strong> \u2013 private market opportunity<\/td><\/tr>
Zhifei Vaccine Franchise<\/strong><\/td>Established HPV, meningococcal, pneumococcal<\/strong> portfolio; DTaP-Hib adds pediatric core combination<\/strong> to capture birth cohort<\/td><\/tr>
Competitive Dynamics<\/strong><\/td>Sanofi Pentaxim (DTaP-IPV-Hib, 5-valent) premium-priced; Zhifei positions as cost-competitive quadrivalent alternative<\/strong><\/td><\/tr>
Manufacturing Scale<\/strong><\/td>Zhifei’s Chongqing facility<\/strong> supports 10+ million dose annual capacity<\/strong>; ready for Phase III scale-up<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n